Tratamento
Before starting GLP-1 therapy, providers evaluate far more than weight. Learn what metabolic markers, medical history, and screening criteria shape a safe, personalized treatment plan.
Understanding how GLP-1 dosing works helps you have smarter conversations with your doctor. Here's what to expect from semaglutide and tirzepatide titration schedules.
Same active ingredient, different brand. If you've wondered why two GLP-1 pens might work differently for you despite containing identical compounds, here's what the data actually shows about formulation, dosing, and device differences.
Entenda os riscos regulatórios, logísticos e sanitários de importar canetas para emagrecer de outros países e o que você precisa avaliar antes de tomar essa decisão.
Starting a GLP-1 medication soon? Research suggests the weeks before your first injection matter more than most people realize. Here's what to focus on while you wait.
Brazil's regulatory body has approved multiple new GLP-1 pen formulations recently, marking a significant shift in treatment options for patients with obesity and metabolic conditions. Here's what you need to know about expanded access and what it means for treatment.
Health Canada's decision to authorize a generic version of semaglutide could set an important precedent for Brazil, where Ozempic remains out of reach for many patients due to high costs.
A clear explanation of how GLP-1 receptor agonists promote weight loss through appetite suppression, metabolic changes, and dual-receptor activation.
Curious about which GLP-1 weight loss pen Brazilians search for most? We break down Ozempic, Mounjaro and Wegovy to help you understand your options in Brazil.
Thinking about GLP-1 pens? Here's what you actually need to know about the difference between diabetes pens and weight loss pens, and why the same drug can wear different names.
